| 항목 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $56.33B | N/A | N/A | N/A | $61.16B | N/A |
| Net Income | $1.37B | $1.56B | $-22.00M | $1.29B | $938.00M | $186.00M | $1.82B | $695.00M |
| EPS (Diluted) | $0.77 | $0.88 | $-0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; ...
🔗 emfls.github.io 다른 콘텐츠 보기
2026년 8월 11일에 재검토했으며 실시간 시세나 투자 권유가 아닙니다. 수익을 보장하지 않고 원금 손실이 가능하므로 공시 원문과 최신 재무자료를 직접 확인하고 필요하면 인가된 전문가와 상담하세요.